Welcome to the new midlife crisis. Clichés like buying a red sports car and hair transplants have been ousted by going vegan, cutting back on alcohol and participating in extreme sports, according to a new study. […]
Men, especially, are prone to set health and lifestyle goals at 40, when they’re likely to embrace veganism (24 per cent) and engage in competitive tests of true grit like Tough Mudder obstacle courses at which contestants must plunge themselves in ice water (The Arctic Enema) and risk being shocked by live wires (Electroshock Therapy) while competing (31 per cent). […]
“Entering a new decade is one of many triggers that can prompt us to think about our health,” Jake Williams, lifestyle health advisor at Bupa Health Clinics, told The Telegraph.
However, the dread creeps in earlier for women, who tend to make health-motivated changes at 30. The reckoning typically takes the form of changing eating habits, joining a gym or hiring a personal trainer.
Despite the fact that Alzheimer’s is the most common cause of dementia in older people, there is not a single drug available to treat the condition. (Getty Images/Cultura RF)
Alzheimer’s researchers, patients, and investors were eagerly anticipating the results of a phase 2 study on a potentially promising new medication, called BAN2401, from the drugmakers Biogen and Eisai.
On July 5, the companies released a summary of the findings from a trial of the drug involving 856 patients with early Alzheimer’s, showing the medication could slow the progression of the brain-ravaging illness. On Wednesday afternoon, they presented more details about their findings at the Alzheimer’s Association International Conference in Chicago.
The results have sparked cautious optimism. “Millions of people have Alzheimer’s, and right now it’s a death sentence. So any time we see positive results from a trial that appears to show disease modification, that gives us hope,” said Keith Fargo, director of scientific programs at the Alzheimer’s Association. “But it’s a cautious hope.” […]
If the results are indeed solid, and the drug is approved for market, it could mean people with early-stage Alzheimer’s might be able to keep the disease at bay. It could also mean that we finally have an actual treatment for the disease, and not just its symptoms, available for patients. […]
The results are still preliminary and not yet peer-reviewed or published. […] The drug still needs to pass a phase 3 clinical study and FDA scrutiny. […]
Edd and Cynthia Staton say moving to Ecuador rescued their retirement savings, which had been crushed in the financial crisis of 2008.
Dream retirements can vary, from relaxing on the front porch to swimming in a pine-circled lake.
What most dreams don’t include? Money worries.
Yet that’s a top anxiety in retirement, with most people concerned about paying for health care.
But there’s another way. Instead of staying home and trying to cut costs so you can survive, why not move overseas?
You could save millions on your cost of living, according to a report from InternationalLiving.com, which surveyed several couples who found overseas bargains when they relocated. Cheaper housing. Cheaper health care. Cheaper meals out. Cheaper travel. And maybe best of all, cheaper luxuries. […]
“The cumulative increase in self-esteem going from childhood to young adulthood to midlife was much larger than I expected,” says Richard Robins, a psychology professor at the University of California. […]
Scientists recently combed through numerous studies of self-esteem to chart the average changes that occur from childhood to old age. […]
The team analyzed 331 studies that assessed self-esteem, collectively covering more than 164,000 people between 4 and 94 years old. Self-esteem is measured with questionnaires in which respondents state to what extent they agree with statements such as “I feel that I’m a person of worth, at least on an equal basis with others” or “I wish I could have more respect for myself.”
The investigators discovered that self-esteem tended to rise slightly from ages 4 to 11, remain stagnant from 11 to 15, increase markedly from 15 to 30, and subtly improve until peaking at 60. It stayed constant from 60 to 70 years old, declined slightly from ages 70 to 90, and dropped sharply from 90 to 94. (Fewer studies addressed the oldest and youngest age groups—just a couple each for the 4 to 6 range and 90 to 94 range—so the evidence is weaker for the tail ends of the spectrum.) The results were published in the journal Psychological Bulletin. […]
